AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24579284 — intervention group
Group type: EXPERIMENTAL
Intervention: EvoraKids (Streptococcus uberis KJ2, Streptococcus oralis KJ3, Streptococcus rattus JH1 45, > or = 100 million) probiotics chewable tablets for 30 days
Number of subjects: 60
Study 21614530 — intervention group
Group type: EXPERIMENTAL
Intervention: Box isolation method
Number of subjects: 29
Study 21614530 — intervention group
Group type: COMPARATOR
Intervention: Conventional circumferential pulmonary vein isolation (PVI)
Number of subjects: 29
Study 19222688 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Forensic Nurse Examiner (FNE) program; n=95
Number of subjects: 149
Study 19222688 — intervention group
Group type: COMPARATOR
Intervention: Non-FNE medical professionals; n=54
Number of subjects: 149
Study 17721102 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention programme
Number of subjects: 9645
Study 17721102 — intervention group
Group type: COMPARATOR
Intervention: Standard activities
Number of subjects: 9645
Study 15053240 — intervention group
Group type: EXPERIMENTAL
Intervention: L-T4 treatment
Number of subjects: 43
Study 15053240 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 43
Study 11350463 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron 50 mg orally
Number of subjects: 150
Study 11350463 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg intravenously
Number of subjects: 150
Study 11350463 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally
Number of subjects: 150
Study 9883919 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes group
Number of subjects: 37
Study 9883919 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine induced vasodilatation
Number of subjects: 37
Study 9883919 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study 8140175 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A group
Number of subjects: 21
Study 8140175 — intervention group
Group type: COMPARATOR
Intervention: Type B group
Number of subjects: 21
Study 2686713 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril (ZOF), 30 mg, once daily (n = 18)
Number of subjects: 37
Study 2686713 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT), 25 mg, once daily (n = 19)
Number of subjects: 37
Study 7976 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0
Study 7976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7976 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital
Number of subjects: 0
Study 7976 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam IV drip
Number of subjects: 0
Study 7976 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam IV bolus
Number of subjects: 0
Study 31006801 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 152
Study 31006801 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 152
Study 28731925 — intervention group
Group type: EXPERIMENTAL
Intervention: ThPVB with 0.5% bupivacaine combined with general anaesthesia
Number of subjects: 68
Study 28731925 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia only
Number of subjects: 68
Study 25421934 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed suture (Quill™)
Number of subjects: 64
Study 25421934 — intervention group
Group type: COMPARATOR
Intervention: Non-barbed sutures
Number of subjects: 64
Study 23549581 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily (initially 30 mg for 1 week, then 60 mg for 4 weeks)
Number of subjects: 231
Study 23549581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 21799214 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 8
Study 21799214 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.3 g/kg BM)
Number of subjects: 8
Study 21799214 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine + Sodium bicarbonate
Number of subjects: 8
Study 21799214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 18645344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test (CPT) with 0.9% saline solution infusion
Number of subjects: 43
Study 18645344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test (CPT)
Number of subjects: 43
Study 18645344 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin and NO evaluated together
Number of subjects: 43
Study 16437735 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine regimen (Sang Ju Yin and Yu Ping Feng San) taken orally for 14 days
Number of subjects: 37
Study 16437735 — intervention group
Group type: COMPARATOR
Intervention: Control study without TCM treatment
Number of subjects: 37
Study 12629532 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg/day)
Number of subjects: 31
Study 12629532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 10711928 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol Edmonston‐Zagreb vaccine
Number of subjects: 4327
Study 10711928 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous Edmonston‐Zagreb vaccine
Number of subjects: 4327
Study 10711928 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous Schwarz vaccine
Number of subjects: 4327
Study 10711928 — intervention group
Group type: COMPARATOR
Intervention: Aerosol Schwarz vaccine
Number of subjects: 4327
Study 9180629 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alcohol intake (1.0 g/kg body wt)
Number of subjects: 16
Study 9180629 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 16
Study 8256930 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric antimicrobials received
Number of subjects: 175
Study 8256930 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with resolution of intra-abdominal infection
Number of subjects: 175
Study 8256930 — intervention group
Group type: COMPARATOR
Intervention: Patients with postoperative infectious complications
Number of subjects: 175
Study 8256930 — intervention group
Group type: EXPERIMENTAL
Intervention: Average age
Number of subjects: 175
Study 8256930 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission WBC
Number of subjects: 175
Study 8256930 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of acute appendicitis
Number of subjects: 175
Study 8256930 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative isolate resistance, age, and admission WBC
Number of subjects: 175
Study 2939253 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation group
Number of subjects: 34
Study 2939253 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 34
Study 30624594 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactotripeptide (LTP)
Number of subjects: 64
Study 30624594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 30624594 — intervention group
Group type: EXPERIMENTAL
Intervention: LTP with exercise
Number of subjects: 64
Study 30624594 — intervention group
Group type: EXPERIMENTAL
Intervention: LTP without exercise
Number of subjects: 64
Study 29437573 — intervention group
Group type: EXPERIMENTAL
Intervention: High-amount/vigorous-intensity exercise group in STRRIDE-PD
Number of subjects: 196
Study 29437573 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 kcal/kg per week exercise group in E-MECHANIC
Number of subjects: 196
Study 29437573 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 kcal/kg per week exercise group in E-MECHANIC
Number of subjects: 196
Study 29437573 — intervention group
Group type: COMPARATOR
Intervention: Control group in E-MECHANIC
Number of subjects: 196
Study 27737361 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity laser therapy (Infrared laser, AsGaAI, wavelength of 790 nm, output power of 20 mW, fluence of 6 J/cm2)
Number of subjects: 30
Study 27737361 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study 24587233 — intervention group
Group type: EXPERIMENTAL
Intervention: unguided online self-help
Number of subjects: 236
Study 24587233 — intervention group
Group type: COMPARATOR
Intervention: waitlist control group
Number of subjects: 236
Study 21729372 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-protein supplementation (one or six biscuits daily for 60 days)
Number of subjects: 377
Study 20134330 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir 800/200 mg QD
Number of subjects: 599
Study 20134330 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir 400/100 mg BID
Number of subjects: 599
Study 17295566 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 198
Study 17295566 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined MI and coping skills training (MI + CBT)
Number of subjects: 198
Study 17295566 — intervention group
Group type: COMPARATOR
Intervention: Non-help-seeking group (NHS)
Number of subjects: 198
Study 15005868 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix-tapping task
Number of subjects: 0
Study 15005868 — intervention group
Group type: EXPERIMENTAL
Intervention: Random-interval generation task
Number of subjects: 0
Study 15005868 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-interval generation task
Number of subjects: 0
Study 15005868 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulatory suppression
Number of subjects: 0
Study 11298162 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine and phenylephrine
Number of subjects: 100
Study 11298162 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine alone
Number of subjects: 100
Study 11298162 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylometazoline
Number of subjects: 100
Study 11298162 — intervention group
Group type: COMPARATOR
Intervention: No preparation
Number of subjects: 100
Study 9555757 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (5-mg chewable tablet) once daily at bedtime for 8 weeks
Number of subjects: 336
Study 9555757 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily at bedtime for 8 weeks
Number of subjects: 336
Study 7936950 — intervention group
Group type: EXPERIMENTAL
Intervention: High amount of gaze
Number of subjects: 64
Study 7936950 — intervention group
Group type: COMPARATOR
Intervention: Low amount of gaze
Number of subjects: 64
Study 3348323 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 hours of ejaculatory abstinence
Number of subjects: 10
Study 3348323 — intervention group
Group type: COMPARATOR
Intervention: 120 hours of ejaculatory abstinence
Number of subjects: 10
Study 28734948 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped classroom approach
Number of subjects: 59
Study 28734948 — intervention group
Group type: COMPARATOR
Intervention: Conventional classroom
Number of subjects: 59
Study 28509904 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy emphasizing exercise during behavioral activation (CBT-E)
Number of subjects: 98
Study 28509904 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy with pleasurable low-energy activities (CBT-C)
Number of subjects: 98
Study 28509904 — intervention group
Group type: COMPARATOR
Intervention: Passive waiting list control group (WL)
Number of subjects: 98
Study 26267119 — intervention group
Group type: EXPERIMENTAL
Intervention: Nestorone® (NES) and ethinyl estradiol (EE) CVR
Number of subjects: 120
Study 23937669 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 338
Study 23937669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study 21167340 — intervention group
Group type: EXPERIMENTAL
Intervention: IRA infusion of 10 million CD34(+) cells
Number of subjects: 31
Study 21167340 — intervention group
Group type: COMPARATOR
Intervention: IRA infusion of 5 million CD34(+) cells
Number of subjects: 31
Study 21167340 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CD34(+) cell infusion)
Number of subjects: 31
Study 18198256 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of life support
Number of subjects: 356
Study 18198256 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart documentation of physician recommendations to withdraw life support
Number of subjects: 356
Study 18198256 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussions of patients' wishes
Number of subjects: 356
Study 18198256 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussions of families' spiritual needs
Number of subjects: 356
Study 18198256 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual care involvement
Number of subjects: 356
Study 18198256 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressions of families' wishes to withdraw life support
Number of subjects: 356
Study 17036488 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp acupuncture
Number of subjects: 70
Study 17036488 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 70
Study 14623799 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroanatomic approach (71 patients)
Number of subjects: 608
Study 14623799 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular mapping (537 patients)
Number of subjects: 608
Study 14623799 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal isolation (25 patients)
Number of subjects: 608
Study 14623799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ostial isolation based on PV angiography (102 patients)
Number of subjects: 608
Study 14623799 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided by intracardiac echocardiography (140 patients)
Number of subjects: 608
Study 14623799 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy delivery based on visualization of microbubbles (270 patients)
Number of subjects: 608
Study 14623799 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild and moderate narrowing
Number of subjects: 608
Study 14623799 — intervention group
Group type: EXPERIMENTAL
Intervention: V/Q scans
Number of subjects: 608
Study 14623799 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild narrowing 3 months after ablation
Number of subjects: 608
Study 10828934 — intervention group
Group type: EXPERIMENTAL
Intervention: Multinutrient liquid supplement
Number of subjects: 50
Study 10828934 — intervention group
Group type: COMPARATOR
Intervention: Non-nutritive placebo drink
Number of subjects: 50
Study 9344052 — intervention group
Group type: EXPERIMENTAL
Intervention: Shunted hydrocephalus
Number of subjects: 88
Study 9344052 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrested hydrocephalus
Number of subjects: 88
Study 9344052 — intervention group
Group type: EXPERIMENTAL
Intervention: No hydrocephalus
Number of subjects: 88
Study 9344052 — intervention group
Group type: COMPARATOR
Intervention: Term comparison group
Number of subjects: 88
Study 1586984 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmustine (BCNU) 200 mg/m2 alone
Number of subjects: 0
Study 1586984 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmustine (BCNU) 200 mg/m2 in combination with recombinant human TNF-alpha (rhTNF alpha) 88 micrograms/m2
Number of subjects: 0
Study 1586984 — intervention group
Group type: COMPARATOR
Intervention: Carmustine (BCNU) alone
Number of subjects: 0
Study 1586984 — intervention group
Group type: COMPARATOR
Intervention: Carmustine (BCNU) in combination with TNF
Number of subjects: 0
Study 4051334 — intervention group
Group type: EXPERIMENTAL
Intervention: IV cefamandole
Number of subjects: 105
Study 4051334 — intervention group
Group type: COMPARATOR
Intervention: IV carbenicillin
Number of subjects: 105
Study 30736858 — intervention group
Group type: EXPERIMENTAL
Intervention: Checkpoint blockade based immunotherapy
Number of subjects: 0
Study 30736858 — intervention group
Group type: EXPERIMENTAL
Intervention: RECIST-based efficacy metric
Number of subjects: 0
Study 30736858 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite response rate
Number of subjects: 0
Study 29338751 — intervention group
Group type: EXPERIMENTAL
Intervention: E-course program (12 sessions + 2 booster sessions)
Number of subjects: 84
Study 29338751 — intervention group
Group type: COMPARATOR
Intervention: Conventional didactic drug prevention course (2 sessions)
Number of subjects: 84
Study 26547890 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic circular cyclocoagulation procedure
Number of subjects: 30
Study 26773120 — intervention group
Group type: EXPERIMENTAL
Intervention: BML-positive individuals (BML grade ≥ 2)
Number of subjects: 559
Study 26773120 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (including BML-positive and BML-negative)
Number of subjects: 559
Study 22585378 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day course of oral prednisolone
Number of subjects: 198
Study 20631323 — intervention group
Group type: EXPERIMENTAL
Intervention: High-monounsaturated fatty acid (HMUFA) diet
Number of subjects: 0
Study 20631323 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-complex carbohydrate (LFHCC) diet supplemented with long-chain (n-3) PUFA
Number of subjects: 0
Study 20631323 — intervention group
Group type: COMPARATOR
Intervention: High-saturated fatty acid (HSFA) diet
Number of subjects: 0
Study 20631323 — intervention group
Group type: COMPARATOR
Intervention: Placebo (high-oleic sunflower-seed oil)
Number of subjects: 0
Study 18356189 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-Passive Bilateral Therapy (APBT) for 10-15 min prior to self-directed motor practice
Number of subjects: 32
Study 18356189 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-Passive Bilateral Therapy (APBT)
Number of subjects: 32
Study 18356189 — intervention group
Group type: COMPARATOR
Intervention: Self-directed motor practice (control group)
Number of subjects: 32
Study 15743471 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg subcutaneously every other week)
Number of subjects: 10
Study 15743471 — intervention group
Group type: COMPARATOR
Intervention: Control individuals (healthy individuals, N=20)
Number of subjects: 10
Study 12487388 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir SGC 1200 mg three-times daily plus two NRTIs (arm A)
Number of subjects: 837
Study 12487388 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir SGC 1600 mg twice-daily plus two NRTIs (arm B)
Number of subjects: 837
Study 12487388 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir SGC 1200 mg twice-daily and nelfinavir 1250 mg twice-daily plus a single NRTI (arm C)
Number of subjects: 837
Study 12487388 — intervention group
Group type: COMPARATOR
Intervention: Saquinavir SGC 1600 mg twice-daily (arm B)
Number of subjects: 837
Study 12487388 — intervention group
Group type: COMPARATOR
Intervention: Saquinavir SGC 1200 mg twice-daily and nelfinavir 1250 mg twice-daily (arm C)
Number of subjects: 837
Study 12487388 — intervention group
Group type: COMPARATOR
Intervention: Saquinavir SGC 1200 mg three-times daily (arm A)
Number of subjects: 837
Study 10588092 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg
Number of subjects: 0
Study 10588092 — intervention group
Group type: COMPARATOR
Intervention: Losartan 100 mg
Number of subjects: 0
Study 7783096 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR 240 mg once daily
Number of subjects: 20
Study 7783096 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg once daily
Number of subjects: 20
Study 7783096 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR plus Enalapril
Number of subjects: 20
Study 1958993 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphonuclear elastase test
Number of subjects: 182
Study 1958993 — intervention group
Group type: COMPARATOR
Intervention: Usual prognostic systems (Ranson and Osborne)
Number of subjects: 182
Study 6085365 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20-40 mg/day)
Number of subjects: 60
Study 6085365 — intervention group
Group type: COMPARATOR
Intervention: Oxprenolol (160-320 mg/day)
Number of subjects: 60
Study 31381365 — intervention group
Group type: EXPERIMENTAL
Intervention: Competency-Based Approaches to Community Health (COACH) intervention, consisting of 15 weekly, 90-minute sessions followed by 3 months of twice-monthly health coaching calls.
Number of subjects: 117
Study 31381365 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving a twice-monthly school readiness curriculum for 3 months.
Number of subjects: 117
Study 28669110 — intervention group
Group type: EXPERIMENTAL
Intervention: NDE-positive group (3% of participants)
Number of subjects: 826
Study 28669110 — intervention group
Group type: EXPERIMENTAL
Intervention: NDE-positive group
Number of subjects: 826
Study 28669110 — intervention group
Group type: EXPERIMENTAL
Intervention: Theistic religions (Christianity, Islam, Hinduism)
Number of subjects: 826
Study 26753844 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct anterior approach
Number of subjects: 99
Study 26753844 — intervention group
Group type: COMPARATOR
Intervention: Lateral approach
Number of subjects: 99
Study 26753844 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 99
Study 25252515 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured behavioural management and pharmacological treatment
Number of subjects: 90
Study 25252515 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment
Number of subjects: 90
Study 22372512 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg molindone (5 mg if weight <30 kg)
Number of subjects: 78
Study 22372512 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg molindone (10 mg if weight <30 kg)
Number of subjects: 78
Study 22372512 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg molindone (15 mg if weight <30 kg)
Number of subjects: 78
Study 22372512 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg molindone (20 mg if weight <30 kg)
Number of subjects: 78
Study 20485133 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative warm-up using a virtual reality simulator
Number of subjects: 8
Study 20485133 — intervention group
Group type: COMPARATOR
Intervention: No warm-up
Number of subjects: 8
Study 18271234 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Dazhui (GV 14) and Shenque (CV 8)
Number of subjects: 68
Study 18271234 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (Haloperidol orally)
Number of subjects: 68